<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-8705</journal-id>
<journal-title><![CDATA[CES Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[CES Med.]]></abbrev-journal-title>
<issn>0120-8705</issn>
<publisher>
<publisher-name><![CDATA[Universidad CES]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-87052020000100003</article-id>
<article-id pub-id-type="doi">10.21615/cesmedicina.34.1.1</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Adherencia farmacológica de pacientes con diabetes mellitus en un programa de nefroprotección: una responsabilidad compartida]]></article-title>
<article-title xml:lang="en"><![CDATA[Medication adherence of patients with diabetes mellitus in a nephroprevention program: a shared responsibility]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Trejo-Bastidas]]></surname>
<given-names><![CDATA[Nury Ximena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Eraso-Paredes]]></surname>
<given-names><![CDATA[Jairo Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Contreras-Martínez]]></surname>
<given-names><![CDATA[Heidy Johanna]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad CES Médica general asistencial en COOEMSSANAR IPS ]]></institution>
<addr-line><![CDATA[Pasto ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad CES Médico auditor en EMSSANAR SAS ]]></institution>
<addr-line><![CDATA[Pasto ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad CES Docente ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>01</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>01</month>
<year>2020</year>
</pub-date>
<volume>34</volume>
<numero>1</numero>
<fpage>3</fpage>
<lpage>13</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-87052020000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-87052020000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-87052020000100003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: la diabetes mellitus tipo dos es una enfermedad crónica de gran impacto en salud pública; su mal control clínico está supeditado a la deficiente adherencia farmacológica. Los programas de nefroprotección intentan mejorar el control de esta enfermedad y una adecuada adherencia puede ser una estrategia. El objetivo del estudio fue determinar los factores asociados con la adherencia farmacológica de pacientes con diabetes en el contexto de un programa de nefroprotección.  Materiales y métodos:  estudio transversal analítico en 282 pacientes con diabetes mellitus tipo dos de un programa de nefroprotección en los municipios de Pasto y Túquerres en el año 2017, seleccionados mediante muestreo aleatorio, sistemático estratificado. La adherencia se midió con el test Morisky-Green. La información se obtuvo de bases de datos de las historias clínicas y mediante un cuestionario estructurado. Se efectuaron análisis descriptivo, bivariado y regresión logística binaria multivariada con fines explicativos. Las medidas de asociación fueron razones de prevalencia (RP).  Resultados:  la mediana de la edad fue de 67 años, 33 % fueron hombres y la proporción de adherencia del 68 %; los factores que se asociaron independientemente fueron, ser mujer RP: 1,25 (IC 95 %: 1,02-4,07), hemoglobina glicosilada entre 6 y 6,9 % RP: 1,66 (1,37-11,80), no uso de insulina RP: 1,36 (1,03-8,52), empleo de solo metformina RP: 1,76 (1,76-10,15) y consulta por medicina interna RP: 1,19 (1,19-4,78).  Conclusión: la adherencia farmacológica está influenciada por múltiples factores que no sólo dependen del paciente, sino que involucran también a los profesionales de salud, el tipo de medicación y su disponibilidad, además de asociarse con el control glucémico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  The type two diabetes is a chronic disease of great impact on public health. Its deficient clinical control is subject to poor medication adherence. Nephroprevention programs seek to improve the contro of this disease and an adequate adherence may be a strategy. The aim of this study was to determine the factors associated with medication adherence in patients with diabetes in the context of a nephroprevention program.  Materials and methods:  A cross-sectional study was conducted among 282 patients with type two diabetes mellitus from a nephroprevention program in the municipalities of Pasto and Túquerres in 2017; they were selected by a systematic stratified random sampling. The Morisky-Green test assessed adherence. Information was obtained from databases, medical records and through a structured questionnaire. A descriptive, bivariate analysis and a multivariate binary logistic regression for explanatory purposes were performed. The association measures were prevalence ratios (PR).  Results:  The median age of the participants was 67 years, 33 % were men and the proportion of adherence was 68 %. Factors that were independently associated with adherence were being a wo- man, PR: 1,25 (95% CI: 1,02-4,07), glycosylated hemoglobin between 6 %-6,9 %, PR: 1,66 (1,37-11,80), not using insulin PR: 1,36 (1,03-8,52), use of only metformin PR: 1,76 (1,76-10,15) and consultation by internal medicine, PR: 1,19 (1,19-4,78).  Conclusion:  The adherence to medication is influenced by multiple factors which not only depend on the patient, but also involve health professionals, the type of medication and its availability, as well as being associated with glycemic control]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Diabetes mellitus tipo 2]]></kwd>
<kwd lng="es"><![CDATA[Adherencia al tratamiento]]></kwd>
<kwd lng="es"><![CDATA[Nefroprotección]]></kwd>
<kwd lng="es"><![CDATA[Insuficiencia renal crónica]]></kwd>
<kwd lng="en"><![CDATA[Type 2 diabetes mellitus]]></kwd>
<kwd lng="en"><![CDATA[Medication adherence]]></kwd>
<kwd lng="en"><![CDATA[Nephroprevention]]></kwd>
<kwd lng="en"><![CDATA[Renal Insufficiency]]></kwd>
<kwd lng="en"><![CDATA[Chronic]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roglic]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<collab>World Health Organization</collab>
<source><![CDATA[Global report on diabetes]]></source>
<year>2016</year>
<page-range>86</page-range><publisher-loc><![CDATA[Geneva ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<collab>E-libro C</collab>
<source><![CDATA[Adherencia a los tratamientos a largo plazo pruebas para la acción]]></source>
<year>2004</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edelman]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Polonsky]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type 2 Diabetes in the real world: the elusive nature of glycemic control]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2017</year>
<volume>40</volume>
<edition>11</edition>
<page-range>1425-32</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Rapold]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brüngger]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Reich]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Rosemann]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[One-year adherence to oral antihyperglycemic medication and risk prediction of patient outcomes for adults with diabetes mellitus]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2016</year>
<volume>95</volume>
<edition>26</edition>
<publisher-loc><![CDATA[Baltimore ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[An]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Stuart]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment discontinuation of oral hypoglycemic agents and healthcare utilization among patients with diabetes]]></article-title>
<source><![CDATA[Journal of Diabetes and its Complications]]></source>
<year>2016</year>
<volume>30</volume>
<edition>8</edition>
<page-range>1443-51</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krass]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Schieback]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dhippayom]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence to diabetes medication: a systematic review]]></article-title>
<source><![CDATA[Diabetic Medicine]]></source>
<year>2015</year>
<volume>32</volume>
<edition>6</edition>
<page-range>725-37</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Medina-Morales]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Echeverri-Cataño]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of medication adherence in diabetes mellitus patients on human versus analogue insulins]]></article-title>
<source><![CDATA[Expert Opinion on Drug Safety]]></source>
<year>2017</year>
<volume>16</volume>
<edition>2</edition>
<page-range>133-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez Domínguez]]></surname>
<given-names><![CDATA[GI]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Sánchez]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Gázquez]]></surname>
<given-names><![CDATA[M de los Á]]></given-names>
</name>
<name>
<surname><![CDATA[Agudelo Vélez]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez Jiménez]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherencia terapéutica y control metabólico en pacientes con diabetes mellitus tipo 2, pertenecientes a una insti- tución hospitalaria, de la ciudad de Medellín (Colombia), año 2011.]]></article-title>
<source><![CDATA[Archivos de Medicina]]></source>
<year>2014</year>
<volume>14</volume>
<edition>1</edition>
<page-range>44-50</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zambrano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Duitama]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Posada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Flórez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Percepción de la adherencia a tratamientos en pacientes con factores de riesgo cardiovascular]]></article-title>
<source><![CDATA[Rev Fac Nac Salud Pública]]></source>
<year>2012</year>
<volume>30</volume>
<edition>2</edition>
<page-range>163-74</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waari]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mutai]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gikunju]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Medication adherence and factors associated with poor adherence among type 2 diabetes mellitus patients on follow-up at Kenyatta National Hospital, Kenya.]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Pan Afr Med J ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<collab>Coordinación metodológica de la Cuenta de Alto Costo</collab>
<source><![CDATA[Contenidos mínimos indispensables para la gestión del riesgo renal en un programa de atención a pacientes adultos con enfermedad renal crónica, sin terapia de reemplazo renal en Colombia.]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<collab>Fondo Colombiano de Enfermedades de Alto Costo</collab>
<article-title xml:lang=""><![CDATA[Nefroprotección: Estrategia fundamental para evitar, controlar y retrasar el daño renal.]]></article-title>
<source><![CDATA[Boletín de Información Técnica Especializada]]></source>
<year>2016</year>
<volume>2</volume>
<edition>2</edition>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Terechenko Luhers]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Baute Geymonat]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Zamonsky Acuña]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherencia al tratamiento en pacientes con diagnóstico de diabetes mellitus tipo ii.]]></article-title>
<source><![CDATA[Biomedicina]]></source>
<year>2015</year>
<volume>10</volume>
<edition>1</edition>
<page-range>20-33</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Val Jiménez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Amorós Ballestero]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Visa]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Ferré]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio descriptivo del cumplimiento del tratamiento farmacológico antihipertensivo y validación del tes Morisky y Green]]></article-title>
<source><![CDATA[Atención Primaria]]></source>
<year>1992</year>
<volume>10</volume>
<edition>5</edition>
<page-range>767-70</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Toh]]></surname>
<given-names><![CDATA[MPHS]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validity and reliability of a self-reported measure of medication adherence in patients with Type 2 diabetes mellitus in Singapore: Validation of a medication adherence measure in Singapore]]></article-title>
<source><![CDATA[Diabetic Medicine]]></source>
<year>2012</year>
<volume>29</volume>
<edition>9</edition>
<page-range>e338-44</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Resolución número 4003 de 2008]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zocchetti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Consonni]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bertazzi]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship between prevalence rate ratios and odds ratios in cross-sectional studies]]></article-title>
<source><![CDATA[Int J Epidemiol]]></source>
<year>1997</year>
<volume>26</volume>
<edition>1</edition>
<page-range>220-3</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>Ministerio de Salud</collab>
<source><![CDATA[Normas científicas, técnicas y administrativas para la investigación en salud. Resolución N° 008430 de 1993]]></source>
<year>1993</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bello Escamilla]]></surname>
<given-names><![CDATA[NV]]></given-names>
</name>
<name>
<surname><![CDATA[Montoya Cáceres]]></surname>
<given-names><![CDATA[PA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherencia al tratamiento farmacológico en adultos mayores diabéticos tipo 2 y sus factores asociados]]></article-title>
<source><![CDATA[Gerokomos]]></source>
<year>2017</year>
<volume>28</volume>
<edition>2</edition>
<page-range>73-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Consuegra Cabally]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz Cedeño]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<source><![CDATA[Factores asociados con la adherencia terapéutica en pacientes con diabetes mellitus tipo 2 atendidos en la consulta de medicina interna en un hospital de II nivel de Bogotá]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Bogotá, Colombia ]]></publisher-loc>
<publisher-name><![CDATA[CES]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[De la Rubia JM, Alejandra Cerda MT. Predictores psicosociales de adherencia a la medicación en pacientes con diabetes tipo 2.]]></article-title>
<source><![CDATA[Revista Iberoamericana de Psicología y Salud]]></source>
<year>2015</year>
<volume>6</volume>
<edition>1</edition>
<page-range>19-27</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciechanowski]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Katon]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The patient-provider relationship: attachment theory and adherence to treatment in diabetes]]></article-title>
<source><![CDATA[American Journal of Psychiatry]]></source>
<year>2001</year>
<volume>158</volume>
<edition>1</edition>
<page-range>29-35</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bagonza]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rutebemberwa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bazeyo]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence to anti diabetic medication among patients with diabetes in eastern Uganda; a cross sectional study]]></article-title>
<source><![CDATA[BMC Health Services Research]]></source>
<year></year>
<volume>15</volume>
<edition>1</edition>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[AJS]]></given-names>
</name>
<name>
<surname><![CDATA[Kellar]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Prevost]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Kinmonth]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Sutton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Canny]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence to hypoglycaemic medication among people with type 2 diabetes in primary care.]]></article-title>
<source><![CDATA[Prim Care Diabetes]]></source>
<year>2012</year>
<volume>6</volume>
<edition>1</edition>
<page-range>27-33</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doggrell]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Warot]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association between the measurement of adherence to anti-diabetes medicine and the HbA1c]]></article-title>
<source><![CDATA[International Journal of Clinical Pharmacy]]></source>
<year>2014</year>
<volume>36</volume>
<edition>3</edition>
<page-range>488-97</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paes]]></surname>
<given-names><![CDATA[AHP]]></given-names>
</name>
<name>
<surname><![CDATA[Bakker]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Soe-Agnie]]></surname>
<given-names><![CDATA[CJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of Dosage Frequency on Patient Compliance]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>1997</year>
<volume>20</volume>
<edition>10</edition>
<page-range>1512-7</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoyos Duque]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Arteaga Henao]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz Cardona]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de no adherencia al tratamiento en personas con Diabetes Mellitus tipo 2 en el domicilio. La visión del cuidador familiar]]></article-title>
<source><![CDATA[Invest Educ Enferm]]></source>
<year>2011</year>
<volume>29</volume>
<edition>2</edition>
<page-range>194-203</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mercado-Ramírez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Escobedo-Hidalgo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sarabia-Avalos]]></surname>
<given-names><![CDATA[MÁ]]></given-names>
</name>
<name>
<surname><![CDATA[Ruíz-Gómez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[González-Cerda]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Aceves-Blanco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores que intervienen sobre la adherencia terapéutica en el tratamiento con insulina en pacientes diabéticos tipo II del Hospital Regional de Magdalena, Jalisco]]></article-title>
<source><![CDATA[Revista de Educación y Desarrollo]]></source>
<year>2017</year>
<volume>41</volume>
<page-range>5-16</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhuyan]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Shiyanbola]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Deka]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Isehunwa]]></surname>
<given-names><![CDATA[OO]]></given-names>
</name>
<name>
<surname><![CDATA[Chandak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of gender in cost-related medication nonadherence among patients with diabetes]]></article-title>
<source><![CDATA[J Am Board Fam Med]]></source>
<year>2018</year>
<volume>31</volume>
<edition>5</edition>
<page-range>743-51</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sohn]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[J-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Jang]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health Behaviors and Medication Adherence in Elderly Patients]]></article-title>
<source><![CDATA[American Journal of Health Promotion]]></source>
<year>2017</year>
<volume>31</volume>
<edition>4</edition>
<page-range>278-86</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
